grinboss

Moderna

MRNA

What is it worth to you? Move six assumptions and see what value per share you get, and where you stand against the price and other users.

Value Moderna (MRNA) with your own assumptions and see where you stand against the price and other users.

Its accounts, year by year

Year endSalesGrowthMargin
12/2016108—−170.1%
12/201720689.9%−111.4%
12/2018135−34.4%−252.2%
12/201960−55.4%−772.3%
12/20208031,233.7%−83.4%
12/202118,4712,200.2%72.8%
12/202219,2634.3%50.1%
12/20236,848−64.4%−57.4%
12/20243,236−52.7%−108.7%
12/20251,944−39.9%−133.3%

Sales in millions of dollars. The margin is the operating margin before stock pay, as a percentage of sales. Each row is a fiscal year, by the month it ends. Source: the reports Moderna files with the SEC, the US securities regulator; the latest is for the fiscal year ended December 31, 2025. See the report.

The model's starting point

  • Sales growth, years 1 to 10: −10.0% a year.
  • Sales growth after year 10: 2.5% a year.
  • Operating margin, before stock pay: −10.0% of sales.
  • Working capital needed to grow: −$30.0 per $100 of new sales.
  • Capital spending: 9.9% of sales.
  • Stock pay to employees: 7.5% of sales.
  • Discount rate, the same for every company: 10%.

These are the six assumptions the page starts with; each user moves them as they see fit.

Reference points

They come from its accounts and its share price, compared with the median of the companies on grinboss. They are not a recommendation.

For

  • Its margin has risen over these years, from −170% to −109%.
  • Growing brings it cash: it collects from its customers before it pays its suppliers.
  • Its sales grew 37.8% a year on average over 9 years, from $0.1 billion to $1.9 billion; the median of grinboss companies is 6.6%.

Against

  • Its margin jumps from one year to the next: 196.8 points on average, and up to 688.9 in a single year; the median is 2.8 points.
  • It makes only −$109 of operating profit for every $100 it sells, before stock pay; the median is $18.
  • Over ten years it fell as much as 95% from its high; the median is 56%.
  • Its operating profit plus depreciation and amortization (EBITDA) is negative: it does not earn enough to measure its debt against.

Next results: January 11, 2027.

Other companies in its sector (Health Care)

Mettler Toledo (MTD) · Pfizer (PFE) · Insulet Corporation (PODD) · Regeneron Pharmaceuticals (REGN) · ResMed (RMD) · Revvity (RVTY) · Solventum (SOLV) · Steris (STE) · All companies

Loading the model…